文献速递核素与放射性配体治疗

先进细胞模型用于靶向放射性核素治疗评估:3D 模型较 2D 模型疗效增强

Using advanced cell models for targeted radionuclide therapy evaluation: increased efficacy in 3D versus 2D.
PubMed 文献 · EJNMMI Res · 2026-04-03

该研究比较了源自 PSMA 表达人前列腺癌细胞系 LNCaP 和 PC3-PIP 的 3D 细胞模型(bio-spheroids、MG-spheroids、NG-spheroids)与 2D 细胞模型在 PSMA 表达、[111In]In-PSMA-I&T 摄取及外照射和 [177Lu]Lu-PSMA-I&T 靶向放射性核素治疗(TRT)后活力上的差异,发现 LNCaP MG-spheroids 对 PSMA-TRT 的活力下降显著强于 2D 细胞,尽管其 PSMA 表达和放射性药物摄取更低且放射敏感性相似。

要点

  • LNCaP MG-spheroids 对 PSMA-TRT 的活力下降显著强于 2D 细胞。
  • 该差异出现在 MG-spheroids 的 PSMA 表达和 [111In]In-PSMA-I&T 摄取更低的情况下。
  • bio-spheroids 与 2D 模型在 EBRT 和 PSMA-TRT 后活力无显著差异。

核心结论

  • 尽管 LNCaP MG-spheroids 的 PSMA 表达和放射性药物摄取更低且放射敏感性相似,PSMA-TRT 对其活力的降低仍强于 2D 培养细胞。
  • bio-spheroids 与 2D 细胞模型之间 PSMA-TRT 疗效无差异。
  • 作者假设对 TRT 重要的生物学因素(如交叉照射和放射性药物在 3D 结构内的滞留)在预先形成细胞间相互作用的 MG-spheroids 中体现得更好。

研究设计与样本

  • 研究开发并评估了源自 PSMA 表达人前列腺癌细胞系 LNCaP 和 PC3-PIP 的 3D 细胞模型(bio-spheroids、MG-spheroids、NG-spheroids),并与 2D 细胞模型进行比较。

主要发现

  • EBRT 和 PSMA-TRT 后,bio-spheroids 与 2D 细胞模型在 LNCaP 和 PC3-PIP 细胞中活力均无显著差异。
  • LNCaP MG-spheroids 对 PSMA-TRT 的反应显著优于 2D 培养细胞,尽管其 PSMA 表达水平和 [111In]In-PSMA-I&T 摄取更低。
  • MG-spheroids 与 2D 细胞模型之间放射敏感性无显著差异。

临床怎么用

  • 在核医学临床前研究中可考虑使用更接近临床特征的 3D 细胞模型(如 MG-spheroids)评估 TRT 疗效。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Preclinically, radiopharmaceuticals are currently mainly evaluated in two-dimensional (2D) cell models, which lack clinical features that are relevant for accurate evaluation of targeted radionuclide therapy (TRT) responses. The development of three-dimensional (3D) cell models in the last years offers opportunities to overcome at least parts of the limitations of 2D cell models, but such 3D cell models are currently only rarely used in nuclear medicine research. Moreover, the comparison between 2D and 3D cell models, aimed at demonstrating the potential added value of 3D cell models, is even more scarce. To fill this gap and promote the use of more clinically relevant 3D cell models in nuclear medicine research, we performed such a comparative study. For this, we developed and evaluated 3D cell models derived from the prostate-specific membrane antigen (PSMA)-expressing human cancer cell lines LNCaP and PC3-PIP, by culturing these cells in anti-adhesive round bottom plates (“bio-spheroids”) or by culturing LNCaP cells in Matrigel (MG) or Noviogel-P5K (NG) domes (”MG-spheroids” or “NG-spheroids”). Hereafter, PSMA expression levels and [111In]In-PSMA-I&T uptake were determined and compared between 3D and 2D cell models. Additionally, we assessed cell viability of 3D- versus 2D-cultured cells after external beam radiation therapy (EBRT) and PSMA-TRT using [177Lu]Lu-PSMA-I&T. RESULTS: No significant differences in viability were observed between bio-spheroids versus 2D cell models after EBRT and PSMA-TRT, neither in LNCaP nor in PC3-PIP cells. In contrast, LNCaP MG-spheroids had a significantly better response to PSMA-TRT in comparison to the 2D-cultured cells. This was despite a lower PSMA expression level and lower [111In]In-PSMA-I&T uptake in the MG-spheroids. Importantly, no significant difference in radiosensitivity was observed between these MG-spheroids and the 2D cell model. CONCLUSIONS: Despite lower PSMA expression levels and lower radiopharmaceutical uptake in LNCaP MG-spheroids, and albeit similar radiosensitivity, PSMA-TRT induced a stronger reduction in viability in the MG-spheroids in comparison to the 2D-cultured cells. In contrast, no differences were observed in PSMA-TRT efficacy between bio-spheroids and the 2D cell model. The aforementioned leads to the hypothesis that biological factors important for TRT, e.g. cross-radiation and radiopharmaceutical retention within the 3D cell structure, are better represented in MG-spheroids where cell-cell interactions are already formed prior to radiopharmaceutical incubation.

来源:EJNMMI Res,查看原文。版权归原作者所有。

引用

  1. Klomp MJ, Erkens SE, van den Brink L, et al. Using advanced cell models for targeted radionuclide therapy evaluation: increased efficacy in 3D versus 2D. EJNMMI Res. 2026. PMID: 41931239. doi:10.1186/s13550-026-01393-0

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。